PMVP
PMV Pharmaceuticals Inc.
$1.29
$0.00(0.00%)
39
Overall
60
Value
18
Tech
--
Quality
Market Cap
$68.89M
Volume
381.61K
52W Range
$0.81 - $1.88
Target Price
$5.50
Company Overview
| Mkt Cap | $68.89M | Price | $1.29 |
| Volume | 381.61K | Change | +0.00% |
| P/E Ratio | -1.2 | Open | $1.30 |
| Revenue | -- | Prev Close | $1.29 |
| Net Income | $-58.7M | 52W Range | $0.81 - $1.88 |
| Div Yield | N/A | Target | $5.50 |
| Overall | 39 | Value | 60 |
| Quality | -- | Technical | 18 |
No chart data available
About PMV Pharmaceuticals Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Sector: Industrials
Industry: Pharmaceutical Preparation Manufacturing
Latest News
PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PMVP | $1.29 | 0% | 381.61K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get PMV Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW